Over time, deterioration of the heart muscle leads to cardiomyopathy and heart failure, which is the leading cause of death in DMD. DMD therapies have been under increased scrutiny since last month after the FDA announced it is investigating the death of two pediatric patients with Duchenne Muscular Dystrophy (DMD) following treatment with Sarepta Therapeutics' (SRPT) FDA-approved gene therapy Elevidys. FDA is investigating the risk of acute liver failure with serious outcomes, including hospitalization and death, following Elevidys, and is evaluating the need for further regulatory action, the agency said. On Stocktwits, retail sentiment around Capricor remained unmoved within 'bearish' territory over the past 24 hours while message volume rose from 'low' to 'normal' levels. CAPR's Sentiment Meter and Message Volume as of 8:35 a.m. ET on July 11, 2025 | Source: Stocktwits CAPR stock is down by 17% this year but up by over 148% over the past 12 months.